I can understand your "if" and "when" argument, but the timeline...

I can understand your "if" and "when" argument, but the timeline argument means nothing in today's regenerative medicine environment compared to MSB's early days.

Both Japan and the US have their fast-track approval system set in place for regenerative medicine companies.
I suspect more countries will follow in the coming years.
It took MSB over a decade to only get to where it is now, but younger stem cell companies (such as CYP) will take full advantage of these newly implemented policies. These policies will not only reduce the timeline siginifcantly, but also reduce the cost siginificantly.

It could be that because MSB has been around for so long to only just achieve what it has, that it's shareholders have such a dim 2-dimesional and antiquated view on all other younger regenerative companies.

There are opportunities out there now (such as fast-tracking & real big $ M&A interest) for regenerative medicine companies, that MSB/SI could only dream of a decade ago.